Holen Sie sich die Stockscreener-App
26.22
1.72%
0.4769
Schlusskurs vom Vortag:
$25.74
Offen:
$25.93
24-Stunden-Volumen:
774.09K
Relative Volume:
0.44
Marktkapitalisierung:
$4.16B
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-508.02M
KGV:
-9.1009
EPS:
-2.8807
Netto-Cashflow:
$-419.23M
1W Leistung:
+1.80%
1M Leistung:
+34.14%
6M Leistung:
+54.48%
1J Leistung:
+83.75%
1-Tages-Spanne:
$25.36
$26.76
1-Wochen-Bereich:
$25.05
$26.80
52-Wochen-Spanne:
$12.58
$26.80
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
26.21 | 4.10B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm
Denali Therapeutics stock stays focused on pipeline progress. - AD HOC NEWS
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Denali to sell priority review voucher for $195M cash boost - MSN
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh - TradingView
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to book forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI) - TradingView
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
4DN Forecast — Price Target — Prediction for 2027 - TradingView
Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN) - TradingView
How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing - Stock Traders Daily
Denali Therapeutics options trading jumps to 2,291 contracts By Investing.com - Investing.com India
Denali Therapeutics options trading jumps to 2,291 contracts - Investing.com
Denali Therapeutics stock hits 52-week high at 25.74 USD By Investing.com - Investing.com Nigeria
Denali Therapeutics stock hits 52-week high at 25.74 USD - Investing.com
DNLI Forecast — Price Target — Prediction for 2027 - TradingView
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate - Moomoo
Denali Therapeutics (DNLI) Q1 2026 earnings summary - Quartr
Denali Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $195 Million - Global Legal Chronicle
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II - Yahoo Finance
Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale - Sahm
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million - simplywall.st
Stifel reiterates Buy rating on Denali Therapeutics stock at $41 By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Denali stock, cites launch progress By Investing.com - Investing.com India
Stifel reiterates Buy rating on Denali Therapeutics stock at $41 - Investing.com
Stifel reiterates Buy rating on Denali stock, cites launch progress - Investing.com
Denali to sell priority review voucher for $195M - MSN
Denali Therapeutics StockAnalyst focus and sector check after a quiet news week - AD HOC NEWS
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod - insights.citeline.com
Sector Update: Healthcare Stocks Advance Premarket Thursday - Moomoo
Denali Therapeutics Files 8-K Report Detailing Company Information and Latest Press Release – June 2026 - Minichart
Denali Therapeutics to sell priority review voucher for $195m - Investing.com
Denali Therapeutics to sell priority review voucher for $195m By Investing.com - Investing.com South Africa
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Denali to sell priority review voucher for $195M (DNLI:NASDAQ) - Seeking Alpha
Denali sells Rare Pediatric Disease Priority Review Voucher for $195M to fund neurodegenerative drug development. - Pluang
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):